WelGrace Research Pharmaceuticals
WelGrace Research Pharmaceuticals
is a specialty pharmaceutical business
unit. We develop select new products
and novel, high-quality and
differentiated formulations of existing
critical-care products to deliver
incremental patient benefit in the
management and treatment of
acute conditions.

WelGrace Research Pharmaceutical
unit collaborates with pharmaceutical
companies and biotechnology firms,
bringing the following core capabilities:
  • Rigorous market research and analysis
  • Strong intellectual property positions/strategies
  • Experienced, high-quality management
  • Proven formulation and analytical technology approaches

We have the expertise to develop specialty formulations that expand
the use of existing molecules and provide:














WelGrace Research Pharmaceuticals also develops innovative delivery
routes and systems for re-formulated products through proof of concept,
and forms alliances with commercial partners for the manufacture, sale
and distribution of such technology transfers. These delivery routes
and systems include:
















At WelGrace Research Pharmaceuticals, our approach is to:
  • Develop products and technologies through proof of concept
  • Identify shorter development and strategic regulatory pathways
  • Improve safety and compliance through pre-clinical studies
  • License products to pharmaceutical industry partners for sales and
    marketing
  • Form alliances for strategic co-development
  • Minimize additional clinical investigations
    Clinical
    differentiation   
    that achieves:
  • Synergistic and additive therapeutic
    benefits
  • Reduced side effects
  • Expanded indications
    Pharmacy
    differentiation,   
    resulting in:
  • Increased compliance
  • Greater ease of use
  • Reduced accidental contamination and
    medication errors
    Infusions
    Pulmonary
    delivery
    Subcutaneous/
    transdermal delivery
    Ready-to-use
  • pre-filled
    syringes
  • pre-mixed
    bags
  • emulsions
    and
    nanoparticle
    platform
    Vial/ampoule for
    nebulization
  • Immediate and
    sustained release
    injectables
  • Micro-needle
    patch systems
For more information, contact:
Mr. George Owoo
President and CEO
764 Porter Circle, Lindenhurst, IL 60046
Email:
owoog@welgrace.com
Telephone  224-372-7918, 908-295-1985  FAX 224-372-7464